Why you should be excited about GWPH

GW Pharmaceuticals PLC- ADR

could become one of its kind company if the FDA approves the company's cannabis-based drug for child epilepsy as a late-stage study showed positive results. The company also commenced a Phase 3 clinical trial of Epidiolex as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder. However, the stock has been volatile. It fell to $36 in early March only to bounce back to $84 in the middle of March. Alan Brochstein, The 420 Investor spoke about GW Pharma on the Benzinga PreMarket Prep. "They are making tremendous efforts. I am surprised at what happened at the beginning of the year. Biotech market was melting down, so that was a part of it. Luckily I held positions in the stock," Brochstein told on the show. GW Pharma is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), which is in Phase study for the treatment of Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis Complex. The company also has a pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, schizophrenia and epilepsy. "I like this story. Since, it is biotech, it is risky," he added. Shares of GW Pharma rose 4.46 percent to $86.22. PreMarket Prep is a daily interactive trading show that features interviews with fund managers, financial advisors and executives. Listen to the show live from 8-9:30 a.m. EST here, or listen to the podcast here.